ACCESS TO MEDICINES
Research has shown that many of the new drugs entering the European market have little to no added therapeutic value (ATV), and is therefore not necessarily better than existing treatments. Wemos’ work on medicines focuses on therapeutic advance, based on independent clinical research. We also advocate conditions for public investments in new medicines, and responsible licensing. We aim for development of medicines that address unmet medical needs.